ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
US Tech 100
17,578.00
-0.20%
Dow Jones
39,056.39
0.44%
Brent Oil
83.515
0.78%
Bitcoin
61,483.12
-1.37%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Biora Therapeutics Inc (BIOR) Quote

Biora Therapeutics Inc

Biora Therapeutics Inc (BIOR)

NASDAQ
0.7161
-0.0243
(-3.28%)
At close: May 08 4:00PM
Delayed by 15 minutes
0.722
-0.0184
( -2.49% )
After Hours: 5:05PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.722
Bid
0.72
Ask
0.7437
Volume
133,026
0.715 Day's Range 0.7495
0.585 52 Week Range 6.70
Market Cap
17.067M
Previous Close
0.7404
Open
0.748
Last Trade
10
@
0.722
Last Trade Time
16:54:21
Financial Volume
$ 97,616
VWAP
0.733815
Average Volume (3m)
468,607
Shares Outstanding
23,703,672
Dividend Yield
-
PE Ratio
-0.14
Earnings Per Share (EPS)
-5.24
Revenue
4k
Net Profit
-124.12M

About Biora Therapeutics Inc

Progenity Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Progenity Inc is primarely in the business of services-medical laboratories. For financial reporting their fiscal year ends on December 31st. This page includes all SEC registration de... Progenity Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Progenity Inc is primarely in the business of services-medical laboratories. For financial reporting their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents S-1 Prospectus Current Reports 8-K 10K Annual Reports filed by Progenity Inc.. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.bicara.com
Headquarters
Dover, Delaware, USA
Founded
1970
Biora Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BIOR. The last closing price for Biora Therapeutics was $0.74. Over the last year, Biora Therapeutics shares have traded in a share price range of $ 0.585 to $ 6.70.

Biora Therapeutics currently has 23,703,672 shares outstanding. The market capitalization of Biora Therapeutics is $17.07 million. Biora Therapeutics has a price to earnings ratio (PE ratio) of -0.14.

BIOR Latest News

More News

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial...

May 07 2024
GlobeNewswire Inc.

Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical...

May 06 2024
GlobeNewswire Inc.

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics...

April 30 2024
GlobeNewswire Inc.

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent...

April 08 2024
GlobeNewswire Inc.

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no...

April 04 2024
GlobeNewswire Inc.

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...

April 03 2024
GlobeNewswire Inc.

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into...

April 01 2024
GlobeNewswire Inc.

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug...

March 26 2024
GlobeNewswire Inc.

U.S. Index Futures on the Rise, Oil Prices Show Stability

U.S. index futures are showing an uptrend in pre-market trading this Tuesday, with investors keen on driving a recovery that had previously lifted stocks to their all-time highs, looking to...

March 26 2024
IH Market News

Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial...

March 18 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.07311.24807395990.6490.76980.62252741880.71130331CS
40.0223.142857142860.70.76980.5852559190.65655327CS
12-0.078-9.750.81.990.5854686070.98154379CS
26-1.118-60.76086956521.841.990.5855377081.14659813CS
52-1.838-71.7968752.566.70.5853455451.70743838CS
156-20.778-96.641860465121.528.750.585103328510.2800878CS
260-20.778-96.641860465121.528.750.585103328510.2800878CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CTMXCytomX Therapeutics Inc
$ 7.39
(76.37%)
13.95M
CPOPPop Culture Group Company Ltd
$ 2.60
(52.94%)
182.94k
SEZLSezzle Inc
$ 55.01
(22.95%)
2.73k
LVLULulus Fashion Lounge Holdings Inc
$ 1.79
(16.99%)
180.86k
TARSTarsus Pharmaceuticals Inc
$ 43.00
(15.13%)
10.63k
ETAOETAO International Company Ltd
$ 1.28
(-32.98%)
134.25k
EMKREMCORE Corporation
$ 2.01
(-30.69%)
318.9k
CDLXCardlytics Inc
$ 10.89
(-25.41%)
410.37k
LFMDLifeMD Inc
$ 10.22
(-17.11%)
33.33k
DUOLDuolingo Inc
$ 207.11
(-15.34%)
95.62k
CTMXCytomX Therapeutics Inc
$ 7.39
(76.37%)
13.95M
HOODRobinhood Markets Inc
$ 18.88
(5.77%)
5.28M
CYNCYNGN Inc
$ 0.0908
(-12.36%)
3.53M
ARMARM Holdings PLC
$ 98.90
(-6.76%)
3.06M
CNSPCNS Pharmaceuticals Inc
$ 0.2075
(-13.54%)
2.71M

BIOR Discussion

View Posts
Arnold25764 Arnold25764 1 week ago
Any possible catalyst here?
👍️0
Monksdream Monksdream 4 weeks ago
BIOR new 52 lo
👍️0
Monksdream Monksdream 1 month ago
BIOR new 52 lo
👍️0
Monksdream Monksdream 1 month ago
BIOR 10Q due 3/26
👍️0
Monksdream Monksdream 2 months ago
BIOR under $2
👍️0
glenn1919 glenn1919 2 months ago
BIOR.................................https://stockcharts.com/h-sc/ui?s=BIOR&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
BIOR..................................https://stockcharts.com/h-sc/ui?s=BIOR&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
BIOR new 52 week low
👍️0
Monksdream Monksdream 5 months ago
BOIR new 52 week low
👍️0
Monksdream Monksdream 5 months ago
BIOR new 52 week low
👍️0
TheFinalCD TheFinalCD 5 months ago
https://finviz.com/quote.ashx?t=BIOR&p=d

https://dilutiontracker.com/app/search/BIOR
👍️0
Awl416 Awl416 5 months ago
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
👍️0
retireat40 retireat40 7 months ago
Looked good this morning at 2.66 but a crappy close.
👍️0
Monksdream Monksdream 9 months ago
BIOR Barchart Bottom 100
Biora Therapeutics Inc NASDAQ: BIOR



GoSymbol lookup
Health Care : Biotechnology | Small Cap ValueCompany profile
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and needle-free delivery of biotherapeutics. The Company's therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP and BIOJET. NAVICAP is a targeted oral delivery platform of therapeutics to the site of disease in the GI tract, designed to improve outcomes for patients with inflammatory bowel disease (IBD). The NAVICAP drug delivery device is an investigational, clinical-stage, single-use ingestible device approximately the size of a fish oil capsule. BIOJET is a systemic oral delivery platform of biotherapeutics designed to replace injection with needle-free, oral delivery of molecules for better management of chronic diseases. The Company's targeted therapeutics pipeline programs include NAVICAP, BT-600 and BT-001. Its systemic therapeutics pipeline programs include BIOJET, BT-200 and BT-002.
👍️0

Your Recent History

NASDAQ
BIOR
Biora Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved